Literature DB >> 94388

Thyroid hormone regulation of alpha-adrenergic receptors: studies in rat myocardium.

R S Williams, R J Lefkowitz.   

Abstract

The effects of alterations in thyroid state on cardiac alpha-adrenergic receptors were investigated by the binding of [3H]dihydroergocryptine (DHE), a potent alpha-adrenergic antagonist. In seven experiments, cardiac membranes from euthyroid rats bound 47 +/- 9 fmoles DHE/mg protein (mean +/- SE) at saturation and demonstrated a dissociation constant (KD) of 2.5 +/- 0.4 nM. Hyperthyroidism, produced by parenteral injection of triiodothyronine, significantly reduced the binding of DHE at all concentrations studied. Scatchard analysis showed this reduction of binding to be due largely to a decreased affinity (KD = 4.0 +/- 0.8 nM, p less than 0.05), although possibly due to a decreased number of binding sites as well (29 +/- 7 fmoles/mg protein, p less than 0.10). Hypothyroidism, produced either by oral propylthiouracil or by surgical thyroidectomy, did not produce a significant change in either the number of binding sites for DHE (56 +/- 8 fmoles/mg protein, p less than 0.40) or in binding affinity (KD = 3.1 +/- 0.5 nM, p less than 0.40). Thus, in addition to the regulation of cardiac beta-receptors by thyroid hormone that has been described previously, thyroid hormone exerts a regulatory effect on the characteristics of cardiac alpha-receptors as well. These changes provide a possible molecular mechanism for the thyroid hormone-induced alterations in cardiac responsiveness to alpha-adrenergic stimulation that have been reported previously.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94388     DOI: 10.1097/00005344-197903000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

1.  Vasospastic angina in a patient with hyperthyroidism.

Authors:  U Canpolat; H Sunman; K M Gürses; K Aytemir
Journal:  Herz       Date:  2012-03-11       Impact factor: 1.443

Review 2.  [Alpha-adrenoceptors in the myocardium: incidence and functional significance].

Authors:  A Mügge
Journal:  Klin Wochenschr       Date:  1985-11-04

3.  The Gordon Wilson lecture. Adrenergic receptors: regulation at the biochemical, physiological and clinical levels.

Authors:  R J Lefkowitz
Journal:  Trans Am Clin Climatol Assoc       Date:  1983

4.  Left ventricular function and hyperthyroidism.

Authors:  J P Merillon; P Passa; J Chastre; A Wolf; R Gourgon
Journal:  Br Heart J       Date:  1981-08

5.  Regulation of alpha and beta adrenergic receptors by triiodothyronine in cultured rat myocardial cells.

Authors:  L E Kupfer; J P Bilezikian; R B Robinson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

6.  Triiodothyronine-induced changes in function, metabolism and weight of the rat heart: effects of alpha- and beta-adrenergic blockade.

Authors:  W Zierhut; H G Zimmer
Journal:  Basic Res Cardiol       Date:  1989 Jul-Aug       Impact factor: 17.165

7.  Novel proteins associated with human dilated cardiomyopathy: selective reduction in α(1A)-adrenergic receptors and increased desensitization proteins.

Authors:  Ting Shi; Christine S Moravec; Dianne M Perez
Journal:  J Recept Signal Transduct Res       Date:  2013-02-06       Impact factor: 2.092

8.  Cardiac alpha- and beta-adrenergic receptor alterations in diabetic cardiomyopathy.

Authors:  C E Heyliger; G N Pierce; P K Singal; R E Beamish; N S Dhalla
Journal:  Basic Res Cardiol       Date:  1982 Nov-Dec       Impact factor: 17.165

9.  Demonstration of alpha-adrenoceptors in the rabbit heart by [3H]-dihydroergocryptine binding.

Authors:  H J Schümann; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-09       Impact factor: 3.000

10.  Hypothyroidism modulates beta adrenergic receptor adenylate cyclase interactions in rat reticulocytes.

Authors:  G L Stiles; J M Stadel; A De Lean; R J Lefkowitz
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.